Financial results: Elixinol; Emyria; Epsilon; Avecho; Creso Pharma; AusCann; MGC Pharma; Botanix; Zelira by Martin Lane and Steve Jones March 1, 2023April 30, 2024 Elixinol Wellness reported a 2022 year-end loss of A$10.5m, a 38% improvement on the previous year, […]
Company news: Emyria; Ananda Wellness; InhaleRx; Cann Global; HFA by Steve Jones September 28, 2022April 29, 2024
Strategic review continues at Elixinol as management mull sale or merger by Steve Jones May 4, 2022April 29, 2024
All options on the table for Elixinol as losses narrow by 50% by Martin Lane February 28, 2022April 29, 2024
Company news: Cronos; ECS Botanics; Elixinol; Zelira; Medlab; Emyria; Creso; MGC Pharma; Botanix; Incannex by Martin Lane February 2, 2022April 29, 2024
Elixinol Global AGM approves rebrand to Elixinol Wellness; key appointments confirmed by Martin Lane May 17, 2021April 26, 2024
